23 Sep 2021 Clover’s COVID-19 Vaccine Candidate Demonstrates 79% Efficacy Against Delta in Global Phase 2/3 SPECTRA Trial Dominated by Variants of Concern and Interest
23 Sep 2021 Pfizer and BioNTech Receive First U.S. FDA Emergency Use Authorization of a COVID-19 Vaccine Booster
22 Sep 2021 Johnson & Johnson Announces Real-World Evidence and Phase 3 Data Confirming Strong and Long-Lasting Protection of Single-Shot COVID-19 Vaccine in the U.S.
20 Sep 2021 Gritstone Announces Dosing of First Volunteer in Trial Evaluating Self-Amplifying mRNA as a COVID-19 Vaccine Booster and Immunogenicity Enhancer
20 Sep 2021 Pfizer and BioNTech Announce Positive Topline Results from Pivotal Trial of COVID-19 Vaccine in Children 5 to 11 Years
18 Sep 2021 Gritstone Announces Dosing of First Solid Tumor Patient with Optimized SLATE “Off-the-Shelf” Mutant KRAS-directed Neoantigen Immunotherapy in Phase 2 Clinical Trial
18 Sep 2021 FDA Advisory Committee Votes Unanimously in Favor Of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-risk Populations
15 Sep 2021 IO Biotech Announces Clinical Collaboration with MSD to Evaluate IO102-IO103 with KEYTRUDA® (pembrolizumab) as First-Line Treatment in Metastatic Melanoma Patients in a Phase 3 Trial
15 Sep 2021 Oragenics Initiates COVID-19 Challenge Study Evaluating Multiple Formulations of its SARS-CoV-2 Vaccine Candidate
15 Sep 2021 Tonix Pharmaceuticals Announces Results of Pre-IND Meeting with FDA for TNX-1800 as a Potential Vaccine to Prevent COVID-19
15 Sep 2021 HOOKIPA announces clinical collaboration with Merck & Co., Inc., Kenilworth, NJ., USA to evaluate HB-200 in combination with KEYTRUDA® (pembrolizumab) in patients with advanced head and neck cancers
15 Sep 2021 Johnson & Johnson Ebola Vaccine Regimen Demonstrated Robust and Durable Immune Response in Adults and Children in Data Published in The Lancet Infectious Diseases
15 Sep 2021 Providence Therapeutics Reports PTX-COVID19-B, its mRNA Vaccine for COVID-19, Neutralizes SARS-CoV-2 and Variants of Concern, Including Delta
09 Sep 2021 New Research on SINOVAC’s COVID-19 Vaccine Shows Third Dose More Effective Against COVID-19, including the Delta Variant
09 Sep 2021 Novavax Initiates Phase 1/2 Clinical Trial of Combination Vaccine for COVID-19 and Seasonal Influenza
04 Sep 2021 Moderna Announces Submission of Data to European Medicines Agency for its COVID-19 Vaccine Booster
02 Sep 2021 Moderna Announces Submission of Initial Data to U.S. FDA for Its COVID-19 Vaccine Booster
02 Sep 2021 Pfizer Announces Start of Phase 3 Clinical Trial in Adults for Its Investigational Vaccine Against Respiratory Syncytial Virus (RSV)
02 Sep 2021 Bavarian Nordic Reports Positive Results from Human Challenge Trial of its RSV Vaccine Candidate
01 Sep 2021 Entos Pharmaceuticals' COVID-19 DNA Vaccine Candidate Approved for Phase 2 Clinical Trial in South Africa
01 Sep 2021 SK bioscience and GSK start Phase 3 trial of adjuvanted COVID-19 vaccine candidate
31 Aug 2021 HDT Bio Corp and Gennova Complete Phase 1 Trial of COVID-19 RNA Vaccine in India
31 Aug 2021 AC Immune Announces First Positive Cognitive Results for a Tau-Targeting Monoclonal Antibody in Alzheimer’s Disease
31 Aug 2021 Johnson & Johnson and Global Partners Announce Results from Phase 2b Imbokodo HIV Vaccine Clinical Trial in Young Women in Sub-Saharan Africa
26 Aug 2021 Moderna Completes Submission of Biologics License Application to the U.S. Food and Drug Administration for its COVID-19 Vaccine

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2020 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up